Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ: BLCM) announced that an abstract detailing early results from a Phase 1 clinical trial of BPX-601, its lead GoCAR-T^® product, has been accepted for presentation at the 2023 ASCO Genitourinary Cancers Symposium. The trial focuses on patients with metastatic castration-resistant prostate cancer and will be showcased on February 16, 2023, in San Francisco. This presentation highlights Bellicum's innovative approach to CAR-T cell therapies, aiming for greater efficacy in cancer treatment through controllable cell signaling technologies.

Positive

• Acceptance of Phase 1 trial results for BPX-601 for presentation at ASCO GU 2023.
• Focus on metastatic castration-resistant prostate cancer, indicating a targeted approach in treatment.

Negative

• None.

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T^® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.

Details of the poster presentation are as follows:

Title: Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR-T Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Poster Board: E1, Abstract 140
Presenter: Mark N. Stein, M.D.
Time/Location: Thursday, February 16, 2023, 2:30 p.m. ET / 11:30 a.m. PT, Level 1, West Hall, Moscone Center

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn. ​

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com

FAQ

What is the significance of Bellicum Pharmaceuticals' BPX-601 in cancer treatment?

BPX-601 is a novel GoCAR-T^® candidate aimed at treating metastatic castration-resistant prostate cancer, potentially leading to more effective cancer therapies.

When will the BPX-601 trial results be presented?

The results will be presented on February 16, 2023, during the 2023 ASCO GU Symposium in San Francisco.

What type of cancer does the BPX-601 clinical trial target?

The clinical trial targets metastatic castration-resistant prostate cancer.

How does Bellicum Pharmaceuticals' GoCAR-T^® technology work?

GoCAR-T^® technology utilizes advanced cell signaling methods to enhance the efficacy of CAR-T cell therapies.

What are the potential implications of the BPX-601 trial results for Bellicum's stock?

Positive results from the BPX-601 trial could enhance investor confidence and potentially increase Bellicum's stock value.